Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
AI is great at finding drug candidates — but getting them to market is another story. Formation Bio just raised a $600 million fund to tackle that exact bottleneck, using AI and a leaner clinical research model to cut drug development costs by up to 50%. The biotech startup, backed by a16z and Sequoia, aims to eventually rival pharma giants like Eli Lilly.
AI has proven remarkably good at discovering potential drug candidates — but the costly, slow grind of actually developing them remains a stubborn problem. Formation Bio, a $1.7 billion biotech startup backed by heavyweights like a16z, Sequoia Capital, and Thrive Capital, just raised a $600 million "drug development accelerator" fund to take on that challenge head-on.
The fund will acquire drug molecules and programs, with Formation Bio stepping in to shepherd them through clinical development. CEO Ben Liu's core argument: traditional contract research organizations (CROs) are bloated with billable-hour incentives that inflate costs unnecessarily. By combining AI with centralized operations, Formation believes it can cut clinical trial spending by 30–50%.
Each acquired program will become its own standalone company (a "NewCo"), with early wins sold off to Big Pharma — a modern twist on the hub-and-spoke model. Liu's long-term vision, however, is to build a pharma company on the scale of Eli Lilly or Sanofi.
By the Numbers:
Why it matters: If Formation Bio's model works, it could fundamentally reshape how drugs move from discovery to patients — faster, cheaper, and with fewer bureaucratic hurdles. That's a significant prospect for an industry where development costs routinely run into the billions.
